Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 3 9Phase 1 7Phase 1/2 3Phase 4 1Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Letrozole 6Tamoxifen 4Cisplatin 4Anastrozole 4ribociclib 3exemestane 3Vancomycin 3Specimen Handling 3Nivolumab 3Magnetic Resonance Spectroscopy 3Human Papillomavirus Recombinant Vaccine nonavalent 3Dexamethasone 3Carboplatin 3Bevacizumab 3trametinib 2toripalimab 2encorafenib 2dabrafenib 2binimetinib 2atezolizumab 2asciminib 2Vincristine 2Sodium Chloride 2Rituximab 2Prednisone 2Papillomavirus Vaccines 2Methotrexate 2Medroxyprogesterone Acetate 2Lenalidomide 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × darolutamide × 90 days × Clear all
NCT05348876 2026-05-18

A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

Bayer

Phase 4 Recruiting
50 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡